Literature DB >> 11775130

Blood pressure and angiotensin converting enzyme inhibitor use in hypertensive patients with chronic renal insufficiency.

C Y Hsu1, D W Bates, G J Kuperman, G C Curhan.   

Abstract

BACKGROUND: Hypertension treatment is important in managing chronic renal insufficiency (CRI). Little is known, however, about the blood pressure (BP) control achieved or the pattern of antihypertensive drug prescription among CRI patients.
METHODS: Using computerized medical records, we studied 3,089 adult hypertensive subjects treated at Brigham and Women's Hospital (Boston, MA) from 1990 through 1998. All subjects had at least two serum creatinine measurements 2 years apart, at least two BP readings, and online weight (to estimate Cockcroft-Gault creatinine clearance [CrCl]).
RESULTS: The average mean arterial pressure over time (mean MAP) was 103 +/- 9 mm Hg among those with CrCI >60 mL/min, 102 t 9 mm Hg among those with CrCl 41 to 60 mL/min. and 101 +/- 9 mm Hg among those with CrCl 21 to 40 mL/min. There were no significant differences in mean MAP among the different categories of renal function in the multivariate analysis (P = .26 for trend). The proportion of patients with final systolic BP < 160 mm Hg and diastolic BP <90 mm Hg was 68% and did not vary with renal function (P = .68 for trend). The proportion of subjects who were prescribed ACE inhibitors was 38% among those with CrCl >60 mL/min, 36% among those with CrCI 41 to 60 mL/min, and only 27% among those with CrCl 21 to 40 mL/min (P = .003 for trend).
CONCLUSIONS: The BP control achieved among hypertensive CRI subjects, although no worse than that among those without CRI, was found to be suboptimal. Patients with CrCl 21 to 40 mL/min were less likely to be prescribed ACE inhibitors than were those with CrCl >60 mL/min. Improvement is needed in the clinical management of these factors that can influence the progression of CRI.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11775130     DOI: 10.1016/s0895-7061(01)02202-6

Source DB:  PubMed          Journal:  Am J Hypertens        ISSN: 0895-7061            Impact factor:   2.689


  3 in total

Review 1.  Delivery patterns of recommended chronic kidney disease care in clinical practice: administrative claims-based analysis and systematic literature review.

Authors:  Marie D Philipneri; Lisa A Rocca Rey; Mark A Schnitzler; Kevin C Abbott; Daniel C Brennan; Steven K Takemoto; Paula M Buchanan; Thomas E Burroughs; Lisa M Willoughby; Krista L Lentine
Journal:  Clin Exp Nephrol       Date:  2008-01-05       Impact factor: 2.801

2.  Potential role of differential medication use in explaining excess risk of cardiovascular events and death associated with chronic kidney disease: a cohort study.

Authors:  Nisha Bansal; Chi-yuan Hsu; Malini Chandra; Carlos Iribarren; Stephen P Fortmann; Mark A Hlatky; Alan S Go
Journal:  BMC Nephrol       Date:  2011-09-14       Impact factor: 2.388

3.  Multicentre randomized controlled trial of angiotensin-converting enzyme inhibitor/angiotensin receptor blocker withdrawal in advanced renal disease: the STOP-ACEi trial.

Authors:  Sunil Bhandari; Natalie Ives; Elizabeth A Brettell; Marie Valente; Paul Cockwell; Peter S Topham; John G Cleland; Arif Khwaja; Meguid El Nahas
Journal:  Nephrol Dial Transplant       Date:  2015-09-30       Impact factor: 5.992

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.